Sildenafil Citrate in Waldenstrom's Macroglobulinemia

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.

Clinical Trial Description

- Sildenafil will be given orally (at home) at a reduced dose for the first week, then each week for 3 more weeks, the dose will be increased. If the patient has no major side effects, then they will receive the maximal dose for 2 years. If they have major side effects, then the dose of the drug might be lowered or the drug stopped.

- Sildenafil will be continued until their is disease progression or serious side effects.

- While patients are receiving sildenafil, they will be seen in the clinic on months 1,2,9,15 and 21 for blood tests and a subject questionnaire. They will also be seen on months 3,6,12,18 and 24 for a physical exam, blood test, physical assessment test, CT scans of chest, abdomen and pelvis, and a subject questionnaire.

- At the end of the study (month 24) a physical exam, blood tests, physical assessment test and a questionnaire will be conducted.

- Follow-up includes clinic visits at month 27,33,39 and 45 for blood tests and a questionnaire as well as visits at month 30,36,42 and 48 for physical exam, blood tests, physical assessment test, bone marrow aspirate and biopsy, CT scans of chest, abdomen and pelvis, and a questionnaire. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00165295
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	September 2005
Completion date	June 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02566265` - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients	Phase 2
Completed	`NCT00422656` - Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00150462` - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies	Phase 1
Terminated	`NCT00142168` - CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia	Phase 2
Suspended	`NCT02439138` - Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia	Phase 2
Completed	`NCT01470196` - Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00250926` - Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia	Phase 2
Active, not recruiting	`NCT03225716` - A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia	Phase 1/Phase 2
Terminated	`NCT01744912` - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies	Phase 1
Completed	`NCT02363439` - Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401	Phase 1/Phase 2
Completed	`NCT00976248` - Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia	Phase 2
Terminated	`NCT00575965` - Simvastatin in Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00919139` - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.	N/A
Completed	`NCT01614821` - Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia	Phase 2
Active, not recruiting	`NCT01078974` - Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia	Phase 1
Completed	`NCT00481871` - Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies	Phase 1/Phase 2
Completed	`NCT00142116` - Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT02092909` - Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia	Phase 1/Phase 2
Completed	`NCT00807677` - A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies	Phase 1
Completed	`NCT01046006` - Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia	Phase 2